Tag
MAPS
- MAPS publishes extensive research paper on ibogaine
- Mexican ibogaine clinic sees increasing number of veteran guests
- Colorado students interested in psychedelics gain access to US$1.5M grant
- Weedmaps parent company stock spikes after proposition to go private
- MAPS partners with diverse artist lineup for psychedelic music & education initiative
- FDA gives long-awaited green light to veterans cannabis trial for PTSD
- Investors wince as FDA panel rejects proposal to approve 'molly' for PTSD therapy
- MAPS subsidiary raises over US$100M to support MDMA regulation
- Billionaire Steve Cohen's Point 72 hedge fund takes 8.1% stake in Cybin
- MDMA-assisted therapy significantly reduces moderate to severe PTSD symptoms
- Optimi Health to supply MDMA for new psychedelic therapy program at Numinus clinics
- Psycheceutical Bioscience develops non‑psychoactive ketamine topical for PTSD and depression
- Beckley Waves establishes ethics council for the psychedelics sector
- New survey aims to gather data on psychedelic use worldwide
- American Medical Association approves medical code for psychedelic therapies coverage
- Sage Institute receives grant to help continue its psychedelic therapy in California
- MAPS now providing digital psychedelic education
- MAPS has immense fundraising success
- Numinus completes Novamind acquisition, upgrades leadership team
- Vancouver Island University to launch Canada's first psychedelic-assisted therapy graduate program
- Field Trip Health opens clinic in Vancouver: Q&A with founder Ronan Levy
- FDA lifts ban on study of therapists taking MDMA
- 67% of PTSD sufferers drop diagnosis in first MDMA Phase 3 trial
- Attend next week's psychedelics legalization debate
- Low‑THC weed led to poor results in major PTSD study
- Canada could regulate psychedelic therapy within few years, bets company